Urolithiasis pp 97-100 | Cite as

Macromolecular Inhibitors

  • F. L. Coe
  • J. H. Parks
  • Y. Nakagawa


Urine from mammalian kidneys inhibits the growth of calcium oxalate monohydrate (COM) crystals (1). Because dialysis reduces inhibition only slightly, the major inhibitors must be molecules too large to dialyze. One of the inhibitor molecules is a glycoprotein we have named nephrocalcin because it is of renal origin and contains the amino acid, gamma-carboxyglutamic acid (Gla), characteristic of the bone protein, osteocalcin (2).


Renal Cell Carcinoma Calcium Oxalate Proximal Tubule Cell Calcium Oxalate Monohydrate Calcium Oxalate Monohydrate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Y Nakagawa, Y Abram, and FL Coe, Isolation of calcium oxalate crystal growth inhibitor from rat kidney and urine, Am. J. Physiol. 247: F765 (1984).PubMedGoogle Scholar
  2. 2.
    Y Nakagawa, HC Margolis, S Yokoyama, FJ Kezdy, ET Kaiser, and FL Coe, Purification and characterization of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium, J. Biol. Chem. 256: 3936 (1981).PubMedGoogle Scholar
  3. 3.
    WG Robertson and M Peacock, Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers, Clin. Sci. 43: 499 (1972).PubMedGoogle Scholar
  4. 4.
    E Worcester, S Kumar, Y Nakagawa, C Wabner, J Hunt, and FL Coe, Relationship of surface adsorption to crystal growth inhibition by nephrocalcin, a urinary glycoprotein inhibitor of calcium oxalate crystal growth: functional and immunochemical comparison to albumin and Tamm-Horsfall protein, J. Clin. Invest. In press (1988).Google Scholar
  5. 5.
    Y Nakagawa, V Abram, JH Parks, SH Lau, JK Kawooya, and FL Coe, Urine glycoprotein crystal growth inhibitors: Evidence for a molecular abnormality in calcium oxalate nephrolithiasis, J. Clin. Invest. 76: 1455 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    Y Nakagawa, M Ahmed, S Hall, S Deganello, and FL Coe, Isolation from human calcium oxalate renal stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth: evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gammacarboxyglutamic acid, J. Clin. Invest. 79: 1782 (1987).PubMedCrossRefGoogle Scholar
  7. 7.
    D Sirivongs, Y Nakagawa, WK Vishny, and FL Coe, Evidence that mouse renal proximal tubule cells produce nephrocalcin, Am. Soc. Nephrol. November, 1988 (Abstract).Google Scholar
  8. 8.
    D Sirivongs, Y Nakagawa, N Vogelzang, and FL Coe, Increase of nephrocalcin (NC) in urine of renal cell carcinoma (RCC) patients: A possible tumor marker for renal cell carcinoma, Am. Soc. Nephrol. November, 1988 (Abstract).Google Scholar
  9. 9.
    B Hess, Y Nakagawa, and FL Coe, Inhibition of calcium oxalate crystal aggregation by nephrocalcin, a urinary inhibitor of calcium oxalate crystal growth: comparison to Tamm Horsfall protein, submitted for publication (1988).Google Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • F. L. Coe
    • 1
  • J. H. Parks
    • 1
  • Y. Nakagawa
    • 1
  1. 1.The Nephrology Program, Pritzker School of MedicineUniversity of ChicagoChicagoUSA

Personalised recommendations